99 Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer.
http://www.nejm.org/doi/full/10.1056/NEJMoa1505270
98 A Bronchial Genomic Classifier for the Diagnostic Evaluation of Lung Cancer.
http://www.nejm.org/doi/full/10.1056/NEJMoa1504601
97 Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
http://www.nejm.org/doi/full/10.1056/NEJMoa1504030
96 Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer.
http://www.nejm.org/doi/full/10.1056/NEJMoa1504627
95 Detection of somatic mutations and HPV in the saliva and plasma of patients with head and neck squamous cell carcinomas.
http://stm.sciencemag.org/content/7/293/293ra104
94 Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer.
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(14)62223-6/abstract
93 Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer.
http://www.nejm.org/doi/full/10.1056/NEJMoa1501824
92 Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.
http://jco.ascopubs.org/content/early/2015/05/22/JCO.2014.58.3377.abstract?sid=25367564-a56b-46d4-b1d0-c0af42ba0d65
91 Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer.
http://www.nejm.org/doi/full/10.1056/NEJMoa1414325
90 Rociletinib in EGFR-Mutated Non–Small-Cell Lung Cancer.
http://www.nejm.org/doi/full/10.1056/NEJMoa1413654
89 AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer.
http://www.nejm.org/doi/full/10.1056/NEJMoa1411817
88 Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(14)62004-3/abstract
87 Results of a Trial of PET-Directed Therapy for Early-Stage Hodgkin’s Lymphoma.
http://www.nejm.org/doi/full/10.1056/NEJMoa1408648
86 Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma.
http://www.nejm.org/doi/full/10.1056/NEJMoa1414428?query=featured_home
85 Postsurgical adjuvant or metastatic renal cell carcinoma therapy models reveal potent antitumor activity of metronomic oral topotecan with pazopanib.
http://stm.sciencemag.org/content/7/282/282ra50
84 A 9-Valent HPV Vaccine against Infection and Intraepithelial Neoplasia in Women.
http://www.nejm.org/doi/full/10.1056/NEJMoa1405044
83 Bortezomib-Based Therapy for Newly Diagnosed Mantle-Cell Lymphoma.
http://www.nejm.org/doi/full/10.1056/NEJMoa1412096
82 Goserelin for Ovarian Protection during Breast-Cancer Adjuvant Chemotherapy.
http://www.nejm.org/doi/full/10.1056/NEJMoa1413204
81 Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients.
http://www.nature.com/nature/journal/v519/n7543/full/nature14320.html
80 Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients.
http://www.pnas.org/content/112/11/E1317.abstract
79 Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer.
http://www.nejm.org/doi/full/10.1056/NEJMoa1413513
78 A Randomized, Controlled Trial of Oral Propranolol in Infantile Hemangioma.
http://www.nejm.org/doi/full/10.1056/NEJMoa1404710
77 A chimeric antigen receptor redirects T cells to treat glioblastoma.
http://stm.sciencemag.org/content/7/275/275ra22.abstract
76 Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma.
http://www.nejm.org/doi/full/10.1056/NEJMoa1411321
75 PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma.
http://www.nejm.org/doi/full/10.1056/NEJMoa1411087
74 Immune-mediated antitumor effect by type 2 diabetes drug, metformin.
http://www.pnas.org/content/112/6/1809.abstract
73 Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: Results from a pilot clinical study.
http://stm.sciencemag.org/content/7/269/269ra2
72 Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib.
http://www.nejm.org/doi/full/10.1056/NEJMoa1412690
71 Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma.
http://www.nejm.org/doi/full/10.1056/NEJMoa1406037
70 Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma.
http://www.nejm.org/doi/full/10.1056/NEJMoa1408868
69 Clinical translation of an ultrasmall inorganic optical-PET imaging nanoparticle probe.
http://stm.sciencemag.org/content/6/260/260ra149
68 Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia.
http://www.nejm.org/doi/full/10.1056/NEJMoa1407222?query=featured_home
67 Anti–CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response.
http://stm.sciencemag.org/content/6/254/254ra128.abstract
66 Breast-Cancer Risk in Families with Mutations in PALB2.
http://www.nejm.org/doi/full/10.1056/NEJMoa1400382
65 Preclinical Evidence That PD1 Blockade Cooperates with Cancer Vaccine TEGVAX to Elicit Regression of Established Tumors.
http://cancerres.aacrjournals.org/content/74/15/4042.abstract
64 Enzalutamide in Metastatic Prostate Cancer before Chemotherapy.
http://www.nejm.org/doi/full/10.1056/NEJMoa1405095
63 Immunosignature system for diagnosis of cancer.
http://www.pnas.org/content/111/30/E3072.abstract
62 Aspirin and the Risk of Colorectal Cancer in Relation to the Expression of 15-Hydroxyprostaglandin Dehydrogenase (HPGD).
http://stm.sciencemag.org/content/6/233/233re2
61 Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer.
http://www.nejm.org/doi/full/10.1056/NEJMoa1311107
60 Thyroid Hormone Inactivation in Gastrointestinal Stromal Tumors.
http://www.nejm.org/doi/full/10.1056/NEJMoa1308893
|
